Hybio Pharmaceutical Co., Ltd.
300199
Ранг среди акций
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Цена акции
$3.69
Рыночная капитализация
$3.11B
Изменение (1 день)
-7.75%
Изменение (1 год)
21.56%
Страна
CN
Торговля Hybio Pharmaceutical Co., Ltd. (300199)
Категория
Healthcare
Прибыль Hybio Pharmaceutical Co., Ltd. (300199)
Прибыль на Jun 2026 TTM: $23.66M
Согласно последним финансовым отчетам Hybio Pharmaceutical Co., Ltd., текущая прибыль компании составляет $23.66M. В 2024 году компания получила прибыль $-22.25M, больше, чем прибыли за 2023, которая составила $-72.20M. Отображаемая прибыль на этой странице — это прибыль до уплаты процентов и налогов, или просто EBIT.
История прибыли компании Hybio Pharmaceutical Co., Ltd. с 2007 по 2026
Прибыль в конце каждого года
| Год | Прибыль | Изменить |
|---|---|---|
| 2026 (TTM) | $23.66M | 157.76% |
| 2025 | $9.18M | -141.26% |
| 2024 | $-22.25M | -69.18% |
| 2023 | $-72.20M | 33.59% |
| 2022 | $-54.05M | -1,119.96% |
| 2021 | $5.30M | -105.88% |
| 2020 | $-90.05M | -29.65% |
| 2019 | $-128.00M | 163.83% |
| 2018 | $-48.52M | -190.05% |
| 2017 | $53.88M | 20.99% |
| 2016 | $44.53M | -14.53% |
| 2015 | $52.11M | 73.20% |
| 2014 | $30.08M | 23.42% |
| 2013 | $24.38M | 44.61% |
| 2012 | $16.86M | 13.35% |
| 2011 | $14.87M | 79.07% |
| 2010 | $8.30M | 48.60% |
| 2009 | $5.59M | 70.78% |
| 2008 | $3.27M | 57.76% |
| 2007 | $2.07M | 0.00% |
Прибыль схожих компаний или конкурентов
| Компания | Прибыль | Разница в прибыли | Страна |
|---|---|---|---|
| $3.62B | 15,188.96% |
DE
|
|
| $3.40B | 14,289.34% |
DE
|
|
| $1.72B | 7,183.94% |
JP
|
|
| $930.30M | 3,831.42% |
CH
|
|
| $1.69B | 7,053.10% |
IN
|
